Preferred Name |
Fulvestrant |
|
Synonyms |
7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol Fulvestrant fulvestrant FULVESTRANT Faslodex(ICI 182,780) ICI 182,780 Faslodex ICI 182780 ZD9238 |
|
Definitions |
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04) |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1379 |
|
Accepted_Therapeutic_Use_For |
Hormone receptor-positive metastatic breast cancer |
|
ALT_DEFINITION |
A drug used to treat certain types of breast cancer in postmenopausal women. It is also being studied in the treatment of other types of cancer. Faslodex blocks estrogen activity in the body and is a type of antiestrogen. |
|
CAS_Registry |
129453-61-8 |
|
CHEBI_ID |
CHEBI:31638 |
|
Chemical_Formula |
C32H47F5O3S |
|
code |
C1379 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
Contributing_Source |
CTRP FDA GDC HemOnc |
|
DEFINITION |
A synthetic estrogen receptor antagonist. Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04) |
|
Display_Name |
Fulvestrant |
|
FDA_UNII_Code |
22X328QOC4 |
|
FULL_SYN |
7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol Fulvestrant fulvestrant FULVESTRANT Faslodex(ICI 182,780) ICI 182,780 Faslodex ICI 182780 ZD9238 |
|
Has_Target | ||
Is_Value_For_GDC_Property | ||
label |
Fulvestrant |
|
Legacy Concept Name |
Fulvestrant |
|
Maps_To |
Fulvestrant |
|
NCI_Drug_Dictionary_ID |
43053 |
|
NSC Number |
719276 |
|
PDQ_Closed_Trial_Search_ID |
43053 |
|
PDQ_Open_Trial_Search_ID |
43053 |
|
Preferred_Name |
Fulvestrant |
|
prefixIRI |
Thesaurus:C1379 |
|
Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
UMLS_CUI |
C0935916 |
|
subClassOf |